Avidity Partners Management’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,395,000
Closed -$9.28M 113
2021
Q2
$9.28M Sell
1,395,000
-1,052,700
-43% -$8.93M 0.25% 71
2021
Q1
$22.7M Buy
2,447,700
+840,700
+52% +$10.2M 0.63% 55
2020
Q4
$28.9M Buy
+1,607,000
New +$28.2M 0.94% 38

Other funds holding CRDF

Avidity Partners Management's CRDF Position: Q3 2021 in Review

Avidity Partners Management sold out of Cardiff Oncology (CRDF) in Q3 2021, closing a stake of 1,395,000 shares — an estimated $9.28M sold.

Avidity Partners Management first reported a position in CRDF in Q4 2020 and held it in 3 quarters. The position peaked at $28.9M in Q4 2020. 94 funds tracked by Wall St. Rank hold CRDF as of Q3 2021.

  • Avidity Partners Management reported no remaining Cardiff Oncology position as of Q3 2021 after selling out during the quarter.
  • Avidity Partners Management sold 1,395,000 Cardiff Oncology shares in Q3 2021, an estimated $9.28M.
  • Avidity Partners Management first reported a position in Cardiff Oncology in Q4 2020 and held it in 3 quarters.
  • Avidity Partners Management's Cardiff Oncology position peaked at $28.9M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2021.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.